New method to make lung cancer drug trials more successful

Australian researchers have developed a new method for finding participants in clinical trials of lung cancer drugs, it was announced on Wednesday.

Researchers from Melbourne's Walter and Eliza Hall Institute (WEHI) were optimistic that the new recruitment process will boost the success rate of drugs being trialled as treatments for lung squamous cell carcinoma, the second most common type of lung cancer.

By mimicking the complexity of human tumours with a research tool, the scientists were able to identify a "biomarker" which could serve as an indication as to which patients would better respond to certain drugs, Xinhua news agency reported.

Marie-Liesse Asselin-Labat, the lead author of the study, said patients with the biomarker were more likely to respond positively to fibroglast growth factor receptor (FGFR) drugs.

"We found that high levels of the anti-cancer drug's target, FGFR1, in a patient's tumour ribonucleic acid (RNA) were a better predictor of their potential response to the drug than the current tests that are used," Asselin-Labat said on Wednesday.

Ben Solomon, a medical oncologist from the Peter MacCallum Cancer Centre, said the finding meant future clinical trials could be designed to succeed.

"Fewer than 10 per cent of new cancer drugs make it past phase 1 clinical trials. In many cases this isn't because of the drug itself, but because of a limitation in clinical trial design," Solomon said.

"Understanding which patients are most likely to respond to certain drugs in clinical trials is crucial both for patients to receive the best treatment, and for new drugs to make it to the clinic."

"Hopefully these data will help to improve trial outcomes by recruiting patients who otherwise might not have been matched to the right trial for them," Solomon said.

Source

ᐧ

Comments

ICH GCP requires EC members to be independent of investigator and sponsor to avoid conflicts of interest

Can an Ethics Committee member e.g. layman/chairman or anyone in the committee participate in the trial as a subject? Vidya If an Ethics Committee member becomes a trial subject on a trial that he/she was involved in approving then there has been a major conflict of interest. The following situations need to be considered: ● IEC member reviews study without any prior knowledge of the study, votes, and then afterwards is approached by clinical research team to participate. Possibly this is OK but the member should no longer be part of the IEC that reviews that study. This will be difficult in practice, so therefore it is not advisable. ● IEC member already knows about the study and is voting in order to be able to participate. This is clearly not acceptable and made worse if there is additional financial incentive for the study (e.g. volunteer study). ICH GCP requires Ethics Committee members to be independent of the investigator and the sponsor to avoid confl...

Indian government outlines policies on drug pricing to favor poorer patients, and increase clinical trials

The Indian government is looking to review the existing drug price control measures in order to make medicines more affordable in the country, and at increasing the number of clinical trials taking place in the country, reports The Pharma Letter's India correspondent. In a parallel move, the Health Ministry is also preparing a framework for public private partnership to tackle the menace of non-communicable diseases in the country, In a move that could potentially result in affordable Medicare and health security moving to a larger section of the population, the government is considering a rash of policy measures in favor of poor patients. Talks are also on in government circles to abolish clinical trials on proven drugs that have been approved and marketed for at least two years in the European Union, United States, UK, Australia, Canada and Japan. A draft proposal in this regard has been prepared by the Health Ministry. If instituted, it would reduce the time taken to introduce n...

How drugs work

Prescription Drugs Special Report Ever wonder how the medications you take act in your body? This brief guide explains how several classes of popular drugs work. Thousands of medications are in use today. Here are some of the most common mechanisms by which these drugs achieve their effects: Antibiotic Drugs -- The development of safe and effective drugs to cure infections was arguably the most significant advance in drug development of the 20th century. Perhaps the most famous example is penicillin, which is derived from a toxin produced by the fungus Penicillium notatum that contaminated a laboratory experiment. The Scottish scientist Alexander Fleming noticed that the Penicillium fungus had done something to kill the bacterium Staphylococcus, which is responsible for many human infections. Antibiotics have several modes of action. Penicillin disrupts the cell walls of bacteria, causing them to die. Some other antibiotics interfere with the ability of microorganisms to ...

My Clinical Trials Diary

Search This Blog